Eyecyte RPE
Alternative Names: Eyecyte-RPELatest Information Update: 05 Aug 2025
At a glance
- Originator Eyestem
- Developer Eyestem; Oregon Health & Science University
- Class Eye disorder therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Dry age-related macular degeneration
Most Recent Events
- 18 Jun 2025 Efficacy data from a phase I/II trial in Dry age related macular degeneration released by EyeStem Research
- 18 Jun 2025 Eyestem announced to expand phase-I/II trials in Dry age-related macular degeneration in USA (Subretinal) in the first half of 2026
- 15 Apr 2025 Efficacy and adverse events data from a phase I/II trial in Dry age related macular degeneration released by EyeStem Research